Netherlands· NL-c5c4da56f13e
Imatinib 1A Pharma 100 mg, filmomhulde tabletten
A imatinib product containing imatinibmesilaat, registered in Netherlands by 1A Pharma GmbH. The same ATC class is registered in 15 of our 19 countries.
Checked against CBG-MEB (Netherlands) on
Informational only — not a medical device.
Where it is registered
Imatinib is registered in 15 of 19 countries.
Countries holding a registration under ATC L01EA01 (imatinib), each read from that country’s own register.
- This record: Netherlands, from CBG-MEB (Netherlands)
- 9 of them publish a price we can compare per daily dose
Imatinib · ATC L01EA01
15 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Germany
- Icelandprice
- Ireland
- Italyprice
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of imatinib costs, country by country.
Normalised to the WHO defined daily dose (0.4 g), the median price runs from $2.80 in United States to $41.72 in Switzerland — a ×15 gap.
- 3 markets with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
- US figures are pharmacy acquisition cost (CMS NADAC), not retail
Imatinib · price per daily dose (0.4 g)
USD · FX 28 Sept 2026
- CH Switzerland$41.72
- IT Italy$11.38
- US United States$2.80 (acquisition cost)
The record
At a glance
CBG-MEB (Netherlands)- Active substance
- IMATINIBMESILAAT
- Manufacturer
- 1A Pharma GmbH
- Country
- Netherlands (NL)
- ATC code
- L01EA01
- ATC class
- Imatinib
- Defined daily dose
- 0.4 g, O
- Reimbursed
- Not published by this register
- Source register
- CBG-MEB (Netherlands)
- Last checked
- September 29, 2026
Packs & prices · 1
- cbg_meb_id133539
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
766 interactions on record for imatinib.
Graded by severity as the source publishes them — 114 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Imatinib · interactions on record
766 records
- 114 severe
- 518 moderate
- 23 minor
- 111 info
Most severe, free to view
- CisaprideA03FA02severe
- NaloxegolA06AH03severe
- EliglustatA16AX10severe
- LonafarnibA16AX20severe
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Imatinib in 17 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- CzechiaGLIVECNovartis Europharm Limited, Dublin
- United Statesimatinib mesylateSun Pharmaceutical Industries, Inc.
- FinlandBimatixSTADA Arzneimittel AG
- BelgiumGlivec 100 mgNovartis Europharm
- SwitzerlandGlivec
- SpainGLIVEC 100 mg COMPRIMIDOS RECUBIERTOS CON PELICULANovartis Europharm Limited
- FranceGLIVEC 100 mg, comprimé pelliculéNOVARTIS EUROPHARM (IRLANDE)
- SwedenBimatix 100 mg Filmdragerad tablettSTADA Arzneimittel AG
Authorised across Europe · EMA
The same active substance is authorised in 30 EEA countries. Names it is sold under:
- Austria · Imagerolan, Imatinib 1a Pharma
- Belgium · Imatinib Eg, Imatinib Grindeks
- Bulgaria · Иматиниб Тева Фарма, Меаксин
- Cyprus · Imarem, Imatinib Koanaa 100 Mg
- Czechia · Imanivec, Imatinib Grindeks
- Germany · Imanivec, Imatinib 1 A Pharma
- Denmark · Bimatix, Imatinib "sandoz"
- Estonia · Glipox, Imatinib Grindeks
- Spain · Imatinib Cipla, Imatinib Farmalider
- Finland · Bimatix, Imatinib Hexal
- France · Imatinib Arrow Lab, Imatinib Bgr
- United Kingdom (Northern Ireland) · Imatinib, Imatinib Amarox
- Greece · Imatek, Imatinib Aenorasis
- Croatia · Imakrebin, Meaxin
- Hungary · Imaniver, Imatinib 1 A Pharma
- Ireland · Imatinib Krka D.D., Imatinib Rowex
- Iceland · Bimatix, Glivec
- Italy · Imanivec, Imatinib Dr. Reddy’s
- Liechtenstein · Glivec, Imatinib Accord
- Lithuania · Glipox, Imatinib Grindeks
- Luxembourg · Imatinib, Imatinib Eg
- Latvia · Imatinib Grindeks, Imatinib Inteli
- Malta · Imatinib Tad, Nibix
- Norway · Bimatix, Glivec
- Poland · Imatenil, Meaxin
- Portugal · Imatinib Aurobindo, Imatinib Aurovitas
- Romania · Imakrebin, Imatinib Grindeks
- Sweden · Bimatix, Imatinib Amarox
- Slovenia · Meaxin
- Slovakia · Imatinib Glenmark, Imatinib Grindeks
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of CBG-MEB (Netherlands). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/ef2b3cf0-1f3f-407e-8aaf-e9c047eae46f GET /v1/drugs/ef2b3cf0-1f3f-407e-8aaf-e9c047eae46f?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Filmomhulde tablet",
"route": "Oraal gebruik",
"soort": "RVG",
"source": "cbg_meb",
"smpc_url": "https://www.geneesmiddeleninformatiebank.nl/smpc/h133539_smpc_en.pdf",
"strength": null,
"atc_label": "Imatinib",
"detail_url": "https://www.geneesmiddeleninformatiebank.nl/nl/rvg133539",
"excipients": [
"HYPROMELLOSE 2910 (3 - 15 mPa.s) (E 464)",
"MACROGOL 8000",
"MAGNESIUMSTEARAAT (E 470b)",
"TALK (E 553b)",
"TITAANDIOXIDE (E 171)"
],
"substances": [
"IMATINIBMESILAAT"
],
"leaflet_url": "https://www.geneesmiddeleninformatiebank.nl/bijsluiters/h133539_piluk.pdf",
"authorised_at": "2026/08/17",
"procedure_number": "NL/H/6194/001",
"dispensing_status": "Uitsluitend recept",
"registration_number": "133539",
"additional_monitoring": "N"
}See everything about imatinib.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.